The Effects of Berberine on *Clostridium Perfringens* Induced Necrotic Enteritis in Broiler Chickens

**Abstract**

**Background:** Necrotic Enteritis, caused by *C. perfringens* is a major bacterial disease in chickens that results in substantial economic losses to the poultry industry. Drug resistance and increased pressure to reduce the use of antimicrobial growth promoters has stimulated the need to search for alternatives. This two-part study investigated the use of the natural herbal compound Berberine in broiler chickens for the control of Necrotic Enteritis.

**Methods and findings:** Phase 1 evaluated Berberine in-water at 0.1 g/L and 1.0 g/L *in vivo* against *C. perfringens* induced disease in broiler chickens. Results demonstrated efficacy towards the disease based on significantly decreased mortality and lesion scores at 1.0 ml/L Berberine treatment. Despite this, bodyweight, and feed and water consumption were greatly decreased in treated groups. Bursa of fabricus to bodyweight ratio results indicate there was no distinct damage to the immune system, suggesting palatability of Berberine in-water may have been the principal cause. The follow-up Phase 2 trial investigated the *in vivo* palatability of Berberine in-feed at 2.0 g/kg in non-challenged broiler chickens. Bodyweight, feed consumption and feed conversion ratio were found to not be affected compared to controls. However, water consumption was significantly increased in treated groups.

**Conclusions:** Therefore from the present study, it can be concluded that Berberine has the potential to contribute to the control of Necrotic Enteritis, and that Berberine in-feed treatment alleviates the bird productivity concerns present when Berberine is administered via water.

**Abbreviations:** BW: Bodyweight; BB ratio: Bursa-to-Bodyweight Ratio; FCR: Feed Conversion Ratio; NE: Necrotic Enteritis; SPSS: Statistical Package for the Social Sciences

---

**Introduction**

Berberine is an isoquinoline quaternary alkaloid, and has been identified as the major active component of many plants such as *Coptidis rhizome*, *Huanglian* and *Phellodendri cortex* [1,2]. It has been used for thousands of years in traditional herbal remedies in China and North America for the treatment of intestinal infections including acute gastroenteritis, cholera and bacillary dysentery [3]. This natural compound has drawn extensive attention as a scaffold for drug design with extensive literature and on-going clinical trials against a multitude of diseases [4]. The commercial poultry industry has been facing increasing pressure to reduce the use of antimicrobial growth promoters due to concerns that the use of antibiotics in the feed contributes to the spread of antibiotic-resistant genes by promoting the selection of antibiotic-resistant bacteria in animals [5-7]. Consequently, diseases such as Necrotic Enteritis (NE) have increased in prevalence, with NE related costs in the...
international poultry industry estimated to be in the region of two billion US dollars annually [8-10]. It is understood that the disease is typically caused by toxins produced by the bacterium Clostridium Perfringens [11]. Clinically, NE is characterized by a sudden increase in flock mortality, often without warning [12]. Subclinically, C. perfringens has been found to cause chronic damage to the intestinal mucosa, resulting in decreased digestion and absorption, reduced weight gain and increased feed-conversion ratio [13,14]. As C. perfringens spores are ubiquitous in nature in the environment and are ingested on a continuous basis via poultry feed, predisposing factors such as mucosal damage caused by coccidiosis are generally accepted to be required for this bacterium to cause disease [12,15,16].

Previous studies demonstrate that Berberine is non-lethal in chickens up to dosages of 2000 mg/kg/ bodyweight and was effective in controlling against experimentally induced coccidial infection in chicken [17,18]. This is evident in the significant reduction of sporulated coccidial oocysts found in the faeces of treated birds. However, bloody diarrhea was observed, suggesting the absorptive mucosal surface was still damaged and does not disallow the notion of a C. perfringens outbreak [18]. In view of this, the potential use of Berberine in experimentally induced C. perfringens infection in broiler chickens is investigated for the first time. In addition to the importance of C. perfringens infection in livestock animals, the Clostridia genus is also associated with toxin-related infections in human patients [19,20]. Thereby, this study can also form the basis for further studies in drug discovery and development.

Materials and Methods

Source of material and animals

Berberine was purchased from the Sichuan Yuxin Pharmaceutical Industry Limited Company (Chengdu, China). Day-old Cobb 500 broiler chickens were obtained from Baiada Country Road Hatchery, Tamworth, NSW, Australia.

Phase 1 experimental design

The trial was performed using one hundred and fifty (150) broiler chicks. Chicks were vaccinated and initially handled as described by Wu et al. [21], before placed into positive pressure isolators for the duration of the trial. Each isolator has a floor space of 1.35 m² and a positive pressure HEPA filtered (virus free) air supply from outside of the building. Water and food were provided ad libitum. An experimental ration formulated to resemble a commercial starter ration without any feed additives of either antimicrobiol or anticoccidial activity was fed throughout the study. The treatment groups are depicted in (Table 1). This allowed us to compare, for the first time, the dose response, efficacy, tissue residues and safety of the naturally occurring plant compound Berberine when administered prophylactically to birds in a C. perfringens utilizing proven experimental model [22].

Necrotic enteritis challenge protocol

The disease model used was based on previously validated studies [15,23,24]. The challenge groups were infected at 9 days of age via oral gavage with 5,000 wild-type strain sporulated oocysts each of E. maxima and E. acervulina and 2,500 sporulated oocysts of E. brunetti in 1 mL of 1% (w/v) sterile saline. At 14 days of age, a known pathogenic strain of C. perfringens was administered (type A strain EHE-NE36, CSIRO Livestock Industries, Geelong, Australia), i.e. (~8.0 log10 cfu/chicken). Whenever a challenge treatment was given, control chickens were administered the diluent or vehicle minus the agent, in the same manner as the challenged birds. All birds were sacrificed and autopsied at 16 days of age.

Assessment of effects

Feed and water intake, bodyweight (BW), feed conversion ratio (FCR) as well as NE lesion scores at autopsy were recorded and compared between groups to determine treatment effects. Bodyweight was recorded on day 1 and 16. The mean initial weight of the chicks for all groups was recorded as not significantly different. The NE lesion score was determined according to Prescott et al. [25]. Birds that died prior to autopsy were examined for NE lesion scores. Mortalities determined to be due to NE was recorded. FCR was calculated by the following formulae [26].

\[
FCR = \frac{\text{Total feed consumed by birds in a treatment group}}{\text{Weight gain of surviving birds + Weight gain of dead birds}}
\]

Organs and body systems of chickens from all groups were examined for gross visual pathological changes. Bursa of fabricius were collected, visually examined and gross weight recorded. BW

Table 1: Phase 1 Experimental Design: Challenge and Berberine in-water Treatment Regime.

<table>
<thead>
<tr>
<th>Group</th>
<th>Bird type</th>
<th>Challenge</th>
<th>Treatment</th>
<th>Dosage</th>
<th>Route</th>
<th>Treatment Days</th>
<th>Treatment No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Broiler</td>
<td>Nil</td>
<td>Nil</td>
<td>-</td>
<td>-</td>
<td>1-16</td>
<td>15</td>
</tr>
<tr>
<td>2</td>
<td>Broiler</td>
<td>Nil</td>
<td>Nil</td>
<td>-</td>
<td>-</td>
<td>1-16</td>
<td>15</td>
</tr>
<tr>
<td>3</td>
<td>Broiler</td>
<td>Nil</td>
<td>Berberine</td>
<td>1.0 g/L</td>
<td>In-water</td>
<td>1-16</td>
<td>15</td>
</tr>
<tr>
<td>4</td>
<td>Broiler</td>
<td>Nil</td>
<td>Berberine</td>
<td>1.0 g/L</td>
<td>In-water</td>
<td>1-16</td>
<td>15</td>
</tr>
<tr>
<td>5</td>
<td>Broiler</td>
<td>NE</td>
<td>Nil</td>
<td>-</td>
<td>-</td>
<td>1-16</td>
<td>15</td>
</tr>
<tr>
<td>6</td>
<td>Broiler</td>
<td>NE</td>
<td>Nil</td>
<td>-</td>
<td>-</td>
<td>1-16</td>
<td>15</td>
</tr>
<tr>
<td>7</td>
<td>Broiler</td>
<td>NE</td>
<td>Berberine</td>
<td>0.1 g/L</td>
<td>In-water</td>
<td>1-16</td>
<td>15</td>
</tr>
<tr>
<td>8</td>
<td>Broiler</td>
<td>NE</td>
<td>Berberine</td>
<td>0.1 g/L</td>
<td>In-water</td>
<td>1-16</td>
<td>15</td>
</tr>
<tr>
<td>9</td>
<td>Broiler</td>
<td>NE</td>
<td>Berberine</td>
<td>1.0 g/L</td>
<td>In-water</td>
<td>1-16</td>
<td>15</td>
</tr>
<tr>
<td>10</td>
<td>Broiler</td>
<td>NE</td>
<td>Berberine</td>
<td>1.0 g/L</td>
<td>In-water</td>
<td>1-16</td>
<td>15</td>
</tr>
</tbody>
</table>
and bursa weight were used to calculate the bursa-to-bodyweight (BB) ratio [27].

\[
\text{BB ratio} = \frac{\text{Bursa weight (g)}}{\text{Body weight (g)}} \times 100
\]

**Phase 2 experimental design**

A follow-up study was conducted to determine the feed palatability, water consumption and bird productivity following incorporation of Berberine in-feed at 2.0 g/kg in ninety (90) commercial broiler chicks. Chicks were vaccinated as in Phase 1, before placed into four individual floor pens, each of 22 or 23 chicks. Water and food were provided ad libitum. An identical experimental ration to Phase 1 was fed throughout the study. The treatment groups are depicted in (Table 2), and allowed us to evaluate the effects of Berberine on BW, feed and water consumption and FCR.

**Assessment of effects:** Feed and water intake, BW, FCR were recorded and compared between groups. The mean initial weight of the chicks of all groups was recorded as not significantly different. Birds were examined for gross visual pathological changes. The impact of Berberine at 1.0 g/L in controlling the disease compared to untreated groups based on significantly reduced mortality and lesion scores (Figure 1). No mortalities and NE lesions were observed in the negative control groups and the unchallenged-treated groups; groups 1, 2 and 3, 4 respectively. In NE-challenged birds, untreated groups 5 and 6 resulted in 83% mortality prior to the emergence of drug resistance as a public health concern [29]. This study hoped to find a natural alternative to already known antimicrobials for the control of NE, especially with the emergence of drug resistance as a public health concern [29]. The Phase 1 in vivo trial demonstrated Berberine was extremely effective in controlling *C. perfringens* induced mortality and lesions. A clear dose-response relation was evident with the high concentration showing greatest reduction in lesion score and death. This suggests that the activity can be attributed to the Berberine itself, which is in accordance with previous studies involving treating broilers with Berberine [17,18,30]. The reduction in severity of observed clinical signs in the

**Statistical analyses**

All values were expressed as means ± SEM. Repeated measures one-way ANOVA was used to analyse all the data in Phase 1 Trial. Student’s t-test was used to analyse all the data in Phase 2 Trial. All statistical analyses were performed with the Statistical Package for the Social Sciences (SPSS) 10.0 software (SPSS, Inc., Chicago, IL, USA).

**Results**

**Phase 1 trial**

**Mortality and lesion scores:** Table 3 summarizes the effects of Berberine against *C. perfringens*. Results show significant efficacy of Berberine at 1.0 g/L in controlling the disease compared to untreated groups based on significantly reduced mortality and lesion scores (Figure 1). No mortalities and NE lesions were observed in the negative control groups and the unchallenged-treated groups; groups 1, 2 and 3, 4 respectively. In NE-challenged birds, untreated groups 5 and 6 resulted in 83% mortality prior to autopsy compared to 0% mortality found in the 1.0 g/L Berberine groups 7 and 8. The lower dose 0.1 g/L Berberine groups 9 and 10 resulted in a 79% mortality rate. This dose-response effect is reflected in the lesion scores, with the untreated and low dose Berberine groups having lesion scores of nearly 4 compared to 1 in the high dose Berberine groups.

**BW, feed and water consumption, FCR and BB ratio:** The impact of *C. perfringens* and Berberine at 0.1 g/L and 1.0 g/L on BW, feed and water consumption and FCR is summarized in (Table 4). BW was observed to be adversely affected by both disease and treatment compared to negative control groups (Figure 2). Negative control groups recorded a mean final BW of birds of 595.3 ± 16.26 g, compared to 407.6 ± 7.706 g of challenged-untreated groups. Unchallenged-high dose Berberine was found to have similar final BWs at 408.0 ± 73 g, while challenged-high dose Berberine showed the worst result at 290.5 ± 10.16 g. Feed and water consumption exhibited similar trends, with groups treated with high dose Berberine recorded to have consumed the least feed and water per bird. This translated to highest FCR in challenged-treated groups and lowest FCR in negative control groups. Water consumption was most affected by Berberine, with groups treated with the high dosage drinking less than 50% of the total water consumed on average by the negative control groups; 856.6 ± 79.34 ml and 1796 ± 147 ml respectively. Relevant histopathological lesions were not observed in the bursa of the birds. BB Ratio (Figure 3) was slightly decreased in the challenged groups, apart from groups treated with high dose Berberine.

**Phase 2 trial**

**BW, feed and water consumption and FCR:** Table 5 summarizes the effect of Berberine in-feed at 2.0 g/kg against *C. perfringens*. Bird productivity overall was observed to not be affected by Berberine in-feed. BW was observed to not be significantly different in treated groups and control groups; 628.0 ± 14.22 g and 614.9 ± 14.48 g respectively. Similarly, average feed consumption per bird and FCR were also not affected. Only water consumption was varied, increasing significantly in treated groups at 3,423 ± 59.09 ml/bird compared to 2,330.0 ± 34.88 ml/bird of control groups.

**Discussion**

*C. perfringens*-associated NE is an economic burden for the poultry industry due to the associated mortality, decreased bird productivity and associated increased FCR. This is projected to increase with the reduction of antimicrobial growth promoter use [28]. This study hoped to find a natural alternative to already known antimicrobials for the control of NE, especially with the emergence of drug resistance as a public health concern [29]. The Phase 1 in vivo trial demonstrated Berberine was extremely effective in controlling *C. perfringens* induced mortality and lesions. A clear dose-response relation was evident with the high concentration showing greatest reduction in lesion score and death. This suggests that the activity can be attributed to the Berberine itself, which is in accordance with previous studies involving treating broilers with Berberine [17,18,30]. The reduction in severity of observed clinical signs in the
Figure 1: Berberine in-water treatment effect on NE-challenged broiler chickens:
Berberine administration significantly decreased NE challenge-induced mortality;
Berberine administration significantly prevented NE challenge-induced ileal lesions;
Berberine administration significantly prevented NE induced duodenum lesions;
Berberine administration significantly prevented NE challenge-induced jejunum lesions.

Table 3: Effects of Berberine in-water on Mortality prior to autopsy and NE Lesion Score Summary Data.

<table>
<thead>
<tr>
<th>Group</th>
<th>1,2</th>
<th>3,4</th>
<th>5,6</th>
<th>7,8</th>
<th>9,10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bird type</td>
<td>Broiler</td>
<td>Broiler</td>
<td>Broiler</td>
<td>Broiler</td>
<td>Broiler</td>
</tr>
<tr>
<td>Challenge Details</td>
<td>Nil</td>
<td>Nil</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
</tr>
<tr>
<td>Treatment</td>
<td>Nil</td>
<td>Berberine</td>
<td>Nil</td>
<td>Berberine</td>
<td>Berberine</td>
</tr>
<tr>
<td>Concentration in-water</td>
<td>-</td>
<td>1.0 g/L</td>
<td>-</td>
<td>0.1 g/L</td>
<td>1.0 g/L</td>
</tr>
<tr>
<td>No. Days Treatment</td>
<td>-</td>
<td>16</td>
<td>16</td>
<td>16</td>
<td>16</td>
</tr>
<tr>
<td>No. Birds</td>
<td>30</td>
<td>30</td>
<td>30</td>
<td>30</td>
<td>30</td>
</tr>
<tr>
<td>Mortality % prior to autopsy</td>
<td>0</td>
<td>0</td>
<td>83.5</td>
<td>79.5</td>
<td>0</td>
</tr>
</tbody>
</table>

Median Lesion Scores

- Duodenal Lesion Score (0 absent to 4 severe): 0, 0, 4, 4, 1
- Jejunal Lesion Score (0 absent to 4 severe): 0, 0, 4, 4, 1
- Ileal Lesion Score (0 absent to 4 severe): 0, 0, 4, 4, 1
Table 4: Effects of Berberine in-water on BW, Feed and Water Consumption, FCR and BB Ratio Summary Data.

<table>
<thead>
<tr>
<th>Group</th>
<th>1,2</th>
<th>3,4</th>
<th>5,6</th>
<th>7,8</th>
<th>9,10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bird type</td>
<td>Broiler</td>
<td>Broiler</td>
<td>Broiler</td>
<td>Broiler</td>
<td>Broiler</td>
</tr>
<tr>
<td>Challenge Details</td>
<td>Nil</td>
<td>Nil</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
</tr>
<tr>
<td>Treatment</td>
<td>Nil</td>
<td>Berberine</td>
<td>Nil</td>
<td>Berberine</td>
<td>Berberine</td>
</tr>
<tr>
<td>Concentration in-water</td>
<td>-</td>
<td>1.0 g/L</td>
<td>-</td>
<td>0.1 g/L</td>
<td>1.0 g/L</td>
</tr>
<tr>
<td>No. Days Treatment</td>
<td>-</td>
<td>16</td>
<td>16</td>
<td>16</td>
<td>16</td>
</tr>
<tr>
<td>No. Birds</td>
<td>30</td>
<td>30</td>
<td>30</td>
<td>30</td>
<td>30</td>
</tr>
<tr>
<td>Feed Consumption (Total) (g)</td>
<td>20,517</td>
<td>12,381</td>
<td>17,189</td>
<td>14,788</td>
<td>10,503</td>
</tr>
<tr>
<td>Mean Feed Consumption (g/bird)</td>
<td>707.3 ± 4.71</td>
<td>507.3 ± 85.39</td>
<td>573.0 ± 23.57</td>
<td>524.5 ± 50.61</td>
<td>433.4 ± 47.56</td>
</tr>
<tr>
<td>Water Consumption (Total) (ml)</td>
<td>52,223</td>
<td>21,752</td>
<td>40,807</td>
<td>36,086</td>
<td>20,861</td>
</tr>
<tr>
<td>Mean Water Consumption (ml/bird)</td>
<td>1,796.0 ± 147</td>
<td>870.3 ± 1.1</td>
<td>1,360.0 ± 17.1</td>
<td>1,281.1 ± 103.5</td>
<td>856.7 ± 79.34</td>
</tr>
<tr>
<td>Mean Bodyweight (g)</td>
<td>595.3 ± 16.26</td>
<td>407.6 ± 85.39</td>
<td>408 ± 10.73</td>
<td>379.8 ± 15.85</td>
<td>290.5 ± 10.16</td>
</tr>
<tr>
<td>Mean Bursa Weight (g)</td>
<td>0.857</td>
<td>0.604</td>
<td>1.464</td>
<td>1.580 ± 0.07</td>
<td>1.602</td>
</tr>
<tr>
<td>Bursa-to-Bodyweight Ratio</td>
<td>0.1425 ± 0.009</td>
<td>0.1454 ± 0.007</td>
<td>0.1354 ± 0.006</td>
<td>0.1368 ± 0.006</td>
<td>0.1563 ± 0.008</td>
</tr>
</tbody>
</table>

**Figure 2** NE challenge and Berberine in-water treatment effect on Bird Productivity:
Both NE challenge and Berberine treatment significantly decreased BW of birds; FCR increased with NE challenge and Berberine treatment effect.
Average feed consumption per bird significantly decreased in NE challenge and Berberine treatment groups.
Average water consumption per bird was significantly decreased in NE challenge and Berberine treatment groups.

**Treatment group vs. Nil Group, p<0.01**
***Treatment group vs. Nil Group, p<0.001**
treated groups compared to the untreated groups is likely to be associated with decreased toxin secretion into the intestine, resulting in decreased *C. perfringens* induced damage to the gut. This is supported by the inhibitory intestinal secretory response of Berberine [31-33]. In addition, studies demonstrating the antimicrobial activity of Berberine against Clostridia bacterium is well-documented and suggests a direct inhibition of *C. perfringens* overgrowth [34-37].

Recently, there has also been accumulating evidence that modulation of gut microbiota confers beneficial effects in both humans and animal trials [38]. Berberine has been shown to significantly promote restoration of the intestinal microbiota by countering effects of intestinal damage triggered by antibiotics through the inhibition of Proteobacteria overgrowth [39]. Zhang et al. [40] reports that Berberine enriched short chain fatty acid (SCFA) producing genera of Blautia and Allobaculum by approximately 10-fold, where SCFAs are reported to alleviate inflammation and improve gut barrier function [41,42]. Similarly, Jeong et al. [43] reported that Berberine significantly suppressed pro-inflammatory genes in mice, while another study demonstrated reduction in lipopolysaccharides (LPS)-induced intestinal damage and decreased serum levels of downstream inflammatory cytokines [44]. The acute phase response induced by LPS in broiler chickens is indicated to be largely mitigated by Berberine [30]. Intestinal inflammatory cascades has been associated with NE, however this may be due to the intercurrent nature of coccidiosis and NE disease [12,45]. Other studies have shown that Berberine reduces smooth muscle contraction and intestinal motility and delays intestinal transit time in humans [46]. Therefore, it is likely that Berberine acts in a multitude of ways in the control of experimentally induced NE.

The study results also show decreased BW and increased FCR in all groups compared to negative control groups. The significant impairment in BW in challenged birds is in accordance to previous NE studies [21,23], where it is believed the chronic damage to the intestinal mucosa caused by *C. perfringens* leads to decreased digestion and absorption, and increased FCR [13,14]. However, surprisingly Berberine also proved to be highly detrimental to BW and feed and water consumption. Water consumption decreased by more than 50% in high dose Berberine groups. Thereby the results show a negative effect on bodyweight and FCR from both the disease and Berberine, although the lack of statistical evidence means the FCR data should be taken with a grain of salt. It is hypothesized that rather than Berberine having an adverse effect on the birds systemically, it was more likely that it was a palatability issue where the chickens did not like the taste of Berberine at high dosages in-water. This is supported by the significantly decreased water consumption and the innate bitterness of the Berberine [47,48]. Toxicity studies conducted by the National Toxicology Program have also demonstrated lack of acute, short-term, developmental and genetic toxicity of Berberine [49]. In fact, a broiler study conducted by Zhang et al. [50] suggests dietary supplementation with Berberine in-feed can improve growth performance by enhancing immunity, reducing oxidative stress, and promoting intestinal colonization.

This is reinforced by the BB ratio. The bursa is a primary lymphoid organ in birds and plays a key role in the differentiation of B-lymphocytes and BB ratio is generally accepted as a key indicator of immune system health [51]. Cazaban et al. [52] shows that an ideal BB ratio potential of 0.11 or above should be observed in healthy male Cobb 500 commercial broilers from 7 to 42 days of age housed in isolated conditions. All birds in the present study had BB ratios >0.11, with slightly increased BB ratio in birds treated with high dose Berberine, suggesting Berberine may positively impact the immune system.

Furthermore, the results of the Phase 2 *in vivo* trial reaffirm that the route of administration played a key factor in the adverse bird productivity results of the first trial. Unlike the first trial where Berberine was administered via water, the BW, feed consumption, and FCR were not affected by Berberine in-feed compared to the control groups. Although similarly, there is a lack of statistical evidence for FCR. In addition, water consumption was observed to have significantly increased in treated groups compared to control groups. This suggests Berberine in-feed stimulated thirst in the birds, which may be due to Berberine promoting glucose metabolism [53-55].

The limitations of this study include the experimental design. Increasing the number of birds or adding groups to each treatment would have allowed for statistically significant conclusions to be drawn regarding FCR. Additional control groups receiving the standard treatment regime used for NE control in Phase 1 would have provided comparative data for Berberine efficacy. There should also have been groups treated with a third concentration of Berberine in-water for a more convincing dose-response argument. Similarly, for Phase 2, additional groups with varying concentrations of Berberine in-feed would have confirmed that route of administration was a crucial factor in bird productivity. A challenge model using Berberine in-feed would also have
been a welcome addition. Finally, the strain type A EHE-NE36 is uncommon in industry. As such, the results of the present study are not reflective of the disease in commercial farms as the strain used is considerably more virulent. Although this may be indicative that a lower dose would still be efficacious in practice.

In conclusion, our data suggests that the addition of Berberine in-water at high dose can protect broiler chickens against C. perfringens induced NE. We provide experimental evidence that Berberine in-water protects against mortality and effectively improves the histopathological scores of chickens in the NE disease model. We hypothesize that Berberine acts as an antimicrobial and a modulator of the gut microbiota. Our data also demonstrates that administration of Berberine in-feed alleviated the bird productivity concerns, and surmise that this is due to the feed masking the inherently bitter taste of Berberine. Overall, Berberine is a promising, potential alternative for the control and treatment of NE.

Acknowledgements

This research was conducted with the help of the University of New England, Armidale, NSW, Australia and Veterinary Health Research Ltd, Armidale, NSW, Australia. We are thankful to Professor Steve Walkden-Brown, Associate Professor Shubiao Wu and Bruce Chick for their assistance and expertise. Any errors are our own and should not tarnish the reputations of these esteemed professionals.

Funding

This research was supported by iRicorgpharm Pty Ltd in its initiative to reduce antibiotic usage in livestock.

Competing and Conflicting Interests

No declaration of competing and conflicting interests.
References


11. Songer JG, Meer RR (1996) Genotyping of Clostridium perfringens by Polymerase Chain Reaction is a Useful Adjunct to Diagnosis of Clostridial Enteric Disease in Animals. Anaerobe 2: 197-203.


49 Program NT (2010) Toxicology and carcinogenesis studies of goldenseal root powder (Hydrastis Canadensis) in F344/N rats and B6C3F1 mice (feed studies). National Toxicology Program technical report series 1: 562.


